Загрузка...
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
AIM: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. METHODS: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pego...
Сохранить в:
| Опубликовано в: : | Clinicoecon Outcomes Res |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6386207/ https://ncbi.nlm.nih.gov/pubmed/30858713 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S192235 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|